IRInes Rombach

Ines Rombach

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ines Rombach has a total of 351 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supporting physical activity through co-production in people with severe mental illness (SPACES): study protocol for a pragmatic, parallel-group randomised controlled trial

    by Trys Burke, Philip Hodgson, Gareth Jones, Rebecca J Beeken, Eleanor Bowes, Cindy Cooper, Robert Copeland, Sam Dawson, Matthew Faires, Zoe Guy, et al.

    Life expectancy is reduced by around 15–20 years for people with severe mental illness (SMI) compared with those without this condition. Many early deaths stem from preventable physical health problems linked to behaviours such as poor diet, smoking and low physical activity. Increasing physical activity can improve overall health. People with SMI are typically less active than the general population and supporting them to increase activity could help reduce the life expectancy gap. This study aims to explore the clinical and cost-effectiveness of a co-produced physical activity programme tailored to people with SMI (the SPACES intervention). This two-arm, multi-site, pragmatic, parallel-group randomised controlled superiority trial will assess the clinical and cost-effectiveness of a co-produced physical activity intervention across National Health Service (NHS) mental health trusts in England and health boards in Wales. A total of 550 participants (275 per arm) will be randomised 1:1 into the intervention or usual care arms. The usual care arm will receive treatment as usual, while the intervention arm will receive treatment as usual plus an 18-week physical activity programme comprising walking sessions, indoor activities and community taster sessions. The intervention group will also receive six one-to-one sessions: four long-form consultations (entry, midpoint and one either side of the exit) and two shorter check-ins (between the entry and midpoint and between midpoint and the first exit consultation). The primary outcome is objective accelerometer-derived minutes per day of moderate to vigorous physical activity at 6 months post randomisation. Secondary outcomes are light physical activity, sedentary behaviour, self-reported physical activity and sedentary behaviour, body mass index, depression, anxiety, loneliness, health-related quality of life, healthcare resource use, predictive behaviour and adverse events. Measures will be taken at baseline and at 3, 6 and 12 months post randomisation. This trial was provided ethical approval by the West of Scotland NHS Research Ethics Committee and the Health Research Authority on 14 May 2024 (ref: 24/WS0040). All participants will provide written informed consent before participation. Findings from this study will be shared publicly and disseminated through publication in peer-reviewed journals, conference presentations and social media outlets. ISRCTN23019026.

  • Open Access

    Treatment of Toddler’s Fractures: Study protocol for a multicentre non-inferiority RCT of no-immobilisation or immobilisation

    by Katie Ridsdale, Shammi Ramlakhan, Ines Rombach, Chris Turtle, Steve Goodacre, Daniel C. Perry, Lizzie Swaby, Joshua Milner, Anju Keetharuth, Muniba Aslam, et al.

    Aims: Toddler’s fractures are non-displaced spiral fractures of the lower third of the tibia which are usually sustained during a minor fall. These fractures are surrounded by a thick outer lining of bone (the periosteum), which typically makes them stable. Treatment approaches vary; most clinicians use casts or boots to immobilise the leg, whereas others observe recovery without immobilisation. Both approaches are thought to be safe. Whilst immobilisation protects the leg, it can cause issues with stiffness, recovery and complications. The aim of the ToTs study is to determine whether no-immobilisation is non-inferior to immobilisation in young children with toddler’s fractures. Methods: This randomised controlled trial aims to recruit 494 participants aged 9 months up to their 4th birthday, who present with clinically suspected or radiologically confirmed toddler’s fractures. Most participants are expected to be recruited from emergency departments or fracture clinics. Patients will be randomly allocated 1:1, to either immobilisation or no-immobilisation. The primary outcome is the FLACC (Face, Legs, Activity, Cry, Consolability) behavioural pain assessment completed by parents/guardians at 7 days post randomisation. The primary comparison will assess non-inferiority using a margin of 1 point on the FLACC scale. Secondary outcomes include pain at 3 and 28 days, hospital attendances, need for treatment of pressure ulcers and fracture displacement after randomisation, recovery of mobility, analgesic use, resource use, and satisfaction, collected either by review of medical notes at 28 days, or parent/guardian questionnaires. The cost-effectiveness of the different treatment strategies will also be assessed. Patient and Public Involvement and Engagement informed the study design and will assist with aspects of trial delivery and dissemination. Discussion: The ToTs trial addresses a lack of high-level evidence regarding the management of toddler’s fractures. This will generate evidence to guide clinical practice regarding whether these fractures should be immobilised.

  • Open Access

    A lifelong approach to promote effective self-management in adults with type 1 diabetes: the DAFNEplus research programme including a cluster RCT

    by Simon Heller, Elaine Scott, Jackie Elliott, Esther Herbert, Ines Rombach, Cindy Cooper, Alan Brennan, Dan Pollard, Julia Lawton, David Rankin, et al.

    Background: Dose Adjustment For Normal Eating is a 5-day, group-based clinical education programme for adults with type 1 diabetes, training them in the complex self-management skills, enabling them to optimise both their glycaemic management and quality of life. Although Dose Adjustment For Normal Eating is associated with improvements in many aspects of diabetes management, including psychological outcomes, it has been challenging to maintain the biomedical improvements for longer term, which have remained well above the glucose levels recommended by National Institute for Health and Care Excellence. Objectives: We aimed to develop and evaluate Dose Adjustment For Normal Eating plus , an enhanced version of Dose Adjustment For Normal Eating, to enable improvements in glycaemic management (glycated haemoglobin) without compromising the quality of life. The objectives of the programme were to modify the existing Dose Adjustment For Normal Eating curriculum and evaluate it in a cluster randomised controlled trial. Design: This programme comprised four workstreams. The first three workstreams focused on redevelopment of the Dose Adjustment For Normal Eating intervention to become ‘Dose Adjustment For Normal Eating plus ’: involving revision of the curriculum for a 5-day, group-based programme, including relevant behaviour change techniques (workstream 1); development of a new structured, pro-active, follow-up programme to be delivered by Dose Adjustment For Normal Eating plus facilitators post course to support ongoing diabetes self-management (workstream 2); and development of a new technology interface to help glucose pattern recognition to inform improved self-management (workstream 3). We used mixed methods to review, develop and refine the Dose Adjustment For Normal Eating plus intervention (course, individual support and technological aspects). The intervention was piloted in three National Health Service specialist diabetes centres and was reviewed via two iterative waves before finalisation. Workstream 4 was a cluster randomised controlled trial using a pragmatic, parallel group (1 : 1) allocation design (Dose Adjustment For Normal Eating vs. Dose Adjustment For Normal Eating plus ), with concurrent process and health economic evaluations. The primary biomedical outcome was the between-group difference in glycated haemoglobin at 12 months. The primary psychological outcome was the between-group difference in the impact of type 1 diabetes on quality of life (using Audit of Diabetes-Dependent Quality of Life-15) at 12 months. Setting: The workstreams and the randomised controlled trial were undertaken in university and National Health Service specialist centres in England and Scotland. Participants: Four hundred and seventy-one adults aged ≥ 18 years with confirmed diagnosis of type 1 diabetes participated in the cluster randomised controlled trial, which was 144 fewer than planned and approximately 77% of the planned sample size. Intervention: Dose Adjustment For Normal Eating plus is a standardised 5-day educational course (described above), delivered 1 day per week over 5 weeks in groups, meeting face to face, followed by five individual support sessions over 12 months. An online platform supports the upload, visualisation, pattern recognition and review of glycaemic data for participants and clinicians. Trial outcome measures: In the cluster randomised controlled trial, the primary biomedical outcome was glycaemia, defined as glycated haemoglobin, at 12 months. The primary psychological outcome was the impact of diabetes on quality of life (assessed using the widely recognised scale, Audit of Diabetes-Dependent Quality of Life-15). Key secondary biomedical outcomes included rates and proportions of severe hypoglycaemia and diabetic ketoacidosis. Key secondary psychological outcomes included diabetes-specific distress, diabetes-specific positive well-being and fear of hypoglycaemia. Results: In the primary intention-to-treat population (309), mean glycated haemoglobin reduced from 9.1% to 8.2% (75.9–66.5 mmol/mol) in the Dose Adjustment For Normal Eating group and from 9.1% to 8.1% (75.6–65.1 mmol/mol) in the Dose Adjustment For Normal Eating plus group. The cluster randomised controlled trial showed no evidence of a between-group difference at 12 months in glycated haemoglobin {point estimate [95% confidence interval −0.014 (−0.284 to 0.255); p = 0.915]}, or diabetes-specific quality of life {point estimate [95% confidence interval 0.2 (−0.1 to 0.5); p = 0.21]}. At 12 months, significant between-group differences were observed, favouring Dose Adjustment For Normal Eating plus , in secondary psychological outcomes (diabetes-specific distress, diabetes-specific positive well-being and actions taken to avoid hypoglycaemia). Limitations: Due to trial-suspension during coronavirus disease, we recruited 471 adults to the cluster randomised controlled trial, 144 fewer than planned. Although this reduced overall statistical power, we showed that the difference in glycated haemoglobin between the groups was far below that we considered a meaningful clinical difference (0.5%). Recruitment also meant that more participants were using continuous glucose monitoring, both before and during the trial than we anticipated. This may have reduced additional benefit of the Dose Adjustment For Normal Eating plus intervention on glycated haemoglobin. The pandemic probably influenced diabetes self-management during the trial in both groups. Conclusions: Dose Adjustment For Normal Eating plus did not lead to greater falls in glycated haemoglobin at 12 months compared to Dose Adjustment For Normal Eating, but these falls were double those reported in previous Dose Adjustment For Normal Eating randomised controlled trials. Sixty-eight per cent of participants showed clinically relevant improved glucose levels. Those in Dose Adjustment For Normal Eating plus reported significant falls in diabetes distress, positive well-being and qualitative research reported positive experiences of Dose Adjustment For Normal Eating plus among participants and health professionals. Future work: In view of major improvements in diabetes distress and positive experiences in both participants and health professionals, the Dose Adjustment For Normal Eating executives, who co-ordinate the delivery of Dose Adjustment For Normal Eating courses, are planning to include key elements of Dose Adjustment For Normal Eating plus in future courses, particularly structured support to participants following the course and key elements of the curriculum. Study registration: This study is registered as IRAS: 235621 and ISRCTN: 42908016. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research Programme (NIHR award ref: RP-PG-0514-20013) and is published in full in Programme Grants for Applied Research ; Vol. 14, No. 21. See the NIHR Funding and Awards website for further award information.

  • Open Access

    Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort

    by Jean-Guillaume Letarouilly, Elnaz Saeedi, Raphael Hurtubise, Lija James, Nicola Gullick, Anne Francis, Deepak Jadon, William Tillett, Yvonne Sinomati, Laura Tucker, et al.

    Background/purpose: The treat-to-target (T2T) strategy in psoriatic arthritis (PsA) is supported by International PsA recommendations. The aim of the Multicentre Observational Initiative in Treat-to-Target Outcomes in Psoriatic Arthritis (MONITOR-PsA) cohort was to assess clinical and patient-reported outcomes through pragmatic implementation of a T2T approach. Methods: Patients from secondary care rheumatology departments in the UK were included using a Trials Within Cohorts design if they were 18 years old or over; had a clinical diagnosis of PsA confirmed by the ClAsSification of Psoriatic ARthritis (CASPAR) criteria; active PsA with ≥ 1 tender or swollen joints or enthesis; not previously treated with DMARDs for articular disease. Patients were assessed every 12 weeks using a T2T strategy during the first year of therapy. The primary outcome was the proportion of patients achieving the PsA Disease Activity Score (PASDAS) ‘good’ response at 48 weeks. Findings: We recruited 300 patients, 195 with polyarticular PsA and 105 with oligoarticular (<4 active joints) PsA from April 2018 to October 2022. Sixty-six patients were in an embedded trial of intensive medication, so the analysis population consisted of 234 patients receiving step-up T2T care. At baseline, the median [interquartile range (IQR)] symptom duration prior to PsA diagnosis was 12.0 [4.9, 34.1] months. The mean PsA disease activity was moderate, and 19.7% of patients had structural damage. The proportion of patients achieving the PASDAS ‘moderate’ and ‘good’ responses at 48 weeks were 36/108 (33.3%) (95%CI: 25%-43%) and 39/108 (36.1%) (95%CI: 28%-46%), respectively. DAPSA remission and MDA were achieved in 39/146 (26.7%) and 60/161 (37.3%) patients at 48 weeks, respectively. The majority of patients (117/168 or 69.6%) achieved PSAID patient acceptable symptom state (≤4) at 48 weeks. Interpretation: In this pragmatic routine implementation of a T2T approach, we report results similar to the T2T outcomes in the TICOPA trial, suggesting that a pragmatic T2T approach can be implemented with good outcomes in routine practice.

  • Open Access

    PASHiOn: Personalised Against Standard High tibial Osteotomy, a prospective multi-centre randomised controlled trial: Trial Protocol

    by Harinderjit Singh Gill, Alisdair MacLeod, Lisa Poulton, David Smith, Heidi Fletcher, Vipul Mandalia, Andrew Toms, Patrick Hourigan, James Murray, Allister Trezies, et al.

    Knee osteoarthritis (OA) is common, painful, progressive and disabling, and has significant personal and societal burden, particularly in an ageing population. Whilst knee replacement is successful for very late stage disease, it is inappropriate for earlier stages, leaving few effective treatments available for patients in the “treatment gap” between symptom free and late-stage arthritis. High Tibial Osteotomy (HTO) is a proven surgical treatment providing good long-term outcome, reducing pain and improving function. HTO involves changing the alignment of the tibia to correct improper joint loading. Outcomes of HTO surgery are linked directly to the accuracy of the surgical re-alignment with under-correction resulting in worse outcomes. Inaccuracies occur primarily due to limitations of the current planning and surgical technique. A new method (TOKA) has been devised involving personalisation and digital planning. This method uses a custom personalised surgical guide and plate, tailored to the patient. The aim of the PASHiOn trial is to establish whether digitally planned personalised HTO surgery (TOKA) increases the accuracy of bone correction in comparison to conventional HTO surgery. Embedded within the trial is a nonrandomised pre-RCT technology check and safety assessment of 5 patients (Phase 1), followed by a randomised controlled trial of 88 patients (Phase 2). During Phase 1 of the clinical investigation, 5 patients fulfilling the inclusion criteria will be recruited and assessed in an identical way to the 88 patients recruited in the main trial, but without randomisation. Recruitment of the remaining patients (Phase 2) will take place after the six-week assessment on the fifth patient is complete and the oversight committee supports progression to Phase 2. Patients in Phase 1 and 2 will be followed up in the same manner for a period of up to 15 months from registration (Phase 1) and randomisation (Phase 2) (12 months from surgery).

  • Open Access

    Clinical effectiveness of a child-specific dynamic stretching programme, compared to usual care, for ambulant children with spastic cerebral palsy (SPELL trial): a parallel group randomized controlled trial

    by Tim Theologis, Daniel C. Perry, Ines Rombach, David J. Keene, Ioana R. Marian, Morag Andrew, Catherine Barry, Loretta Davis, Gregory Firth, Heidi Fletcher, et al.

    Aims: Dynamic muscle stretching exercises are one of the interventions frequently prescribed by physiotherapists for children with cerebral palsy (CP). However, there is wide variability in the exercise regimes used and limited evidence of their effectiveness. The SPELL trial will assess the clinical effectiveness of an individually tailored dynamic stretching programme, compared to usual care for ambulant children with spastic CP.Methods: We are conducting a multicentre, two-arm, parallel group, superiority randomized controlled trial. We will recruit children aged four to 11 years with a diagnosis of spastic CP (bilateral or unilateral) and Gross Motor Function Classification System (GMFCS) levels I to III who are able to comply with assessment procedures and exercise programme with or without support. Participants will be recruited from at least 12 UK NHS Trust physiotherapy and related services. Participants (n = 334) will be randomized (centralized computer-generated one:one allocation ratio) to either: 1) a dynamic stretching exercise programme, with six one-to-one physiotherapy sessions over 16 weeks; or 2) usual NHS care, with a single physiotherapy session and an assessment, and advice regarding self-management and exercise.Conclusion: The primary outcome is functional mobility measured using the child-/parent-reported Gait Outcomes Assessment List (GOAL) at six months. Secondary outcomes are: joint range of motion (Cerebral Palsy Integrated Pathway protocol) and motor function (timed up and go test) at six months; functional mobility (GOAL) at 12 months; independence (GOAL subdomain A); balance (GOAL subdomain A, B, D); pain and discomfort (GOAL subdomain C); health-related quality of life (youth version of the EuroQol five-dimension questionnaire (EQ-5D-Y)); educational attendance; exercise adherence; and additional physiotherapy treatment at six and 12 months. The primary analysis will be intention to treat.Cite this article: Bone Jt Open 2025;6(5):506–516.


  • Open Access

    Clinical effectiveness of an individually tailored strengthening programme, including progressive resistance exercises and advice, compared to usual care for ambulant adolescents with spastic cerebral palsy (ROBUST trial): a parallel group randomized controlled trial

    by Sally Hopewell, David J. Keene, Ioana Marian, Daniel C. Perry, Ines Rombach, Morag Andrew, Catherine Barry, Loretta Davis, Gregory Firth, Heidi Fletcher, et al.

    Aims: Muscle strengthening exercises are one of the interventions frequently prescribed by physiotherapists for adolescents with cerebral palsy (CP). However, there is wide variability in the exercise regimes used and limited evidence of their effectiveness. The ROBUST trial will assess the clinical effectiveness of an individually tailored strengthening programme, including progressive resistance exercises and advice, compared to usual care for ambulant adolescents with spastic CP.Methods: We are conducting a multicentre, two-arm, parallel group, superiority randomized controlled trial. We will recruit adolescents aged 12 to 18 years with a diagnosis of spastic CP (bilateral or unilateral) Gross Motor Function Classification System (GMFCS) levels I to III who are able to comply with the assessment procedures and exercise programme with or without support. Participants will be recruited from at least 12 UK NHS Trust physiotherapy and related services. Participants (n = 334) will be randomized (centralized computer-generated 1:1 allocation ratio) to either: 1) a progressive resistance exercise programme, with six one-to-one physiotherapy sessions over 16 weeks; or 2) usual NHS care, with a single physiotherapy session and an assessment session, and advice regarding self-management and exercise.Conclusion: The primary outcome is functional mobility measured using the child-/parent-reported Gait Outcomes Assessment List (GOAL) at six months. Secondary outcomes are: clinician-assessed muscle strength (Five Times Sit-to-Stand Test) and motor function (timed up and go test) at six months; functional mobility (GOAL) at 12 months; independence (GOAL subdomain A), balance (GOAL subdomain A, B, D), pain and discomfort (GOAL subdomain C), health-related quality of life (youth version of the EuroQol five-dimension questionnaire; EQ-5D-Y), educational attendance, exercise adherence, and additional physiotherapy treatment (six and 12 months). The primary analysis will be intention to treat.Cite this article: Bone Jt Open 2025;6(5):517–527.


  • Open Access

    Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT

    by Abhishek Abhishek, Nicholas Peckham, Corinna Pade, Joseph M Gibbons, Lucy Cureton, Catherine J Reynolds, Anne Francis, Vicki Barber, Jennifer Williams, Duncan Appelbe, et al.

    Objective: Methotrexate is first-line treatment for many immune-mediated inflammatory diseases. However, it inhibits vaccine-induced immunity – a major concern for this vulnerable group of patients. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster improved antibody response against spike protein of the receptor binding domain and live virus neutralisation (ancestral Wuhan and Omicron BA.1) in patients with immune-mediated inflammatory diseases. Design: Open-label, prospective, individually randomised, parallel-group, controlled superiority trial with 1 : 1 randomisation. Setting: Multicentre, secondary-care rheumatology and dermatology outpatient clinics. Participants: Adults with immune-mediated inflammatory diseases attending rheumatology and dermatology clinics taking methotrexate (≤ 25 mg/week) for ≥ 3 months. Intervention: Suspending methotrexate treatment for 2 weeks immediately after COVID-19 booster vaccination. Main outcome(s) and measure(s): The primary outcome was spike protein of the receptor binding domain antibody level 4 weeks after COVID-19 booster vaccination. Secondary outcomes were spike protein of the receptor binding domain antibody levels 12 and 26 weeks after COVID-19 vaccine dose; live virus neutralisation (ancestral Wuhan Hu-1, Omicron BA.1) at weeks 4, 12 and 26; and self-reported inflammatory disease activity, flare-ups, quality of life, global assessment of inflammatory disease and adherence with trial allocation. Results: A total of 383 participants (61% female, average age 59.0 years) were randomised to either suspend or continue methotrexate. The geometric mean (95% confidence interval) spike protein of the receptor binding domain antibody titre was 25,413 (22,227 to 29,056) and 12,326 (10,538 to 14,418) U/ml in those who suspended and continued methotrexate, respectively. The geometric mean ratio (95% confidence interval) was 2.08 (1.59 to 2.70), p < 0.0001. The intervention effect was present across prognostic subgroups, for example, age groups, methotrexate dose, methotrexate administration route, diseases and past severe acute respiratory syndrome coronavirus 2 infection. Enhanced antibody responses were sustained at 12 and 26 weeks with geometric mean ratio (95% confidence interval) 1.88 (1.44 to 2.46) and 1.50 (1.12 to 2.01), respectively. Interruption of treatment improved neutralisation of Wuhan and Omicron BA.1 at 4 weeks with geometric mean ratio (95% confidence interval) 2.56 (1.21 to 5.44) and 2.42 (1.45 to 4.05), respectively. Self-reported inflammatory disease activity initially deteriorated in the suspended methotrexate group, but the groups were comparable at week 12. Conclusion: Two-week interruption of methotrexate treatment for immune-mediated inflammatory diseases enhanced antibody responses after COVID-19 vaccination that were sustained at 12 and 26 weeks. Limitations: Lack of participant masking which could have affected self-reported outcomes. Condition-specific disease activity was not used as we recruited participants with a range of diseases, with many lacking validated outcome measures. We did not have data for memory B-cell and T-cell responses. Some hospitals declined to participate in the 26-week follow-up visit which was added to the study after interim analysis, due to lack of capacity, contributing to increased attrition at week 26. Future work: Future research should evaluate whether interrupting other immune-suppressing treatments soon after vaccination against COVID-19 or other infectious diseases can improve immune responses. Further research should also evaluate whether a shorter hold in methotrexate would improve the immune response elicited by vaccination. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation programme as award number NIHR134607.

  • Open Access

    Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial

    by Abhishek Abhishek, Nicholas Peckham, Corinna Pade, Joseph M Gibbons, Lucy Cureton, Catherine J Reynolds, Anne Francis, Vicki Barber, Jennifer Williams, Duncan Appelbe, et al.

    This article consists of a citation of a published article describing research funded by the Efficacy and Mechanism Evaluation programme under project number NIHR134607, and is provided as as part of the complete record of research outputs for this project. The original publication is available at: https://doi.org/10.1016/S2665-9913(23)00298-9 Summary: Background: Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improved antibody response against the S1 receptor binding domain (S1-RBD) of the SARS-CoV-2 spike protein and live SARS-CoV-2 neutralisation compared with uninterrupted treatment in patients with immune-mediated inflammatory diseases. Method: We did a multicentre, open-label, parallel-group, randomised, superiority trial in secondary-care rheumatology and dermatology clinics in 26 hospitals in the UK. Adults (aged ≥18 years) with immune-mediated inflammatory diseases taking methotrexate (≤25 mg per week) for at least 3 months, who had received two primary vaccine doses from the UK COVID-19 vaccination programme were eligible. Participants were randomly assigned (1:1) using a centralised validated computer program, to temporarily suspend methotrexate treatment for 2 weeks immediately after COVID-19 booster vaccination or continue treatment as usual. The primary outcome was S1-RBD antibody titres 4 weeks after COVID-19 booster vaccination and was assessed masked to group assignment. All randomly assigned patients were included in primary and safety analyses. This trial is registered with ISRCTN, ISRCTN11442263; following a pre-planned interim analysis, recruitment was stopped early. Finding: Between Sept 30, 2021, and March 7, 2022, we screened 685 individuals, of whom 383 were randomly assigned: to either suspend methotrexate (n=191; mean age 58·8 years [SD 12·5], 118 [62%] women and 73 [38%] men) or to continue methotrexate (n=192; mean age 59·3 years [11·9], 117 [61%] women and 75 [39%] men). At 4 weeks, the geometric mean S1-RBD antibody titre was 25 413 U/mL (95% CI 22 227-29 056) in the suspend methotrexate group and 12 326 U/mL (10 538-14 418) in the continue methotrexate group with a geometric mean ratio (GMR) of 2·08 (95% CI 1·59-2·70; p<0·0001). No intervention-related serious adverse events occurred. Interpretation: 2-week interruption of methotrexate treatment in people with immune-mediated inflammatory diseases enhanced antibody responses after COVID-19 booster vaccination that were sustained at 12 weeks and 26 weeks. There was a temporary increase in inflammatory disease flares, mostly self-managed. The choice to suspend methotrexate should be individualised based on disease status and vulnerability to severe outcomes from COVID-19. Funding: National Institute for Health and Care Research. Funding: This publication was funded by the Efficacy and Mechanism Evaluation programme as a part of award number NIHR134607. This article reports on one component of the research award Vaccine Response On/Off Methotrexate (VROOM): does temporarily suspending methotrexate treatment for two weeks enhance COVID-19 vaccine response? A randomised controlled trial. For more information about this research please view the award page [https://fundingawards.nihr.ac.uk/award/NIHR134607] DOI: https://doi.org/10.1016/S2665-9913(23)00298-9


  • Open Access

    Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)

    by Abhishek Abhishek, Nicholas Peckham, Corinna Pade, Joseph M Gibbons, Lucy Cureton, Catherine J Reynolds, Anne Francis, Vicki Barber, Jennifer Williams, Duncan Appelbe, et al.

    This article consists of a citation of a published article describing research funded by the Efficacy and Mechanism Evaluation programme under project number NIHR134607, and is provided as as part of the complete record of research outputs for this project. The original publication is available at: https://doi.org/10.1136/bmjopen-2022-062599 Introduction: It is unknown if a temporary break in long-term immune-suppressive treatment after vaccination against COVID-19 improves vaccine response. The objective of this study was to evaluate if a 2-week interruption in low-dose weekly methotrexate treatment after SARS-CoV-2 vaccine boosters enhances the immune response compared with continuing treatment in adults with autoimmune inflammatory conditions. Methods and analysis: An open-label, pragmatic, prospective, parallel group, randomised controlled superiority trial with internal feasibility assessment and nested mechanistic substudy will be conducted in rheumatology and dermatology clinics in approximately 25 UK hospitals. The sample size is 560, randomised 1:1 to intervention and usual care arms. The main outcome measure is anti-spike receptor-binding domain (RBD) antibody level, collected at prebooster (baseline), 4 weeks (primary outcome) and 12 weeks (secondary outcome) post booster vaccination. Other secondary outcome measures are patient global assessments of disease activity, disease flares and their treatment, EuroQol 5- dimention 5-level (EQ-5D-5L), self-reported adherence with advice to interrupt or continue methotrexate, neutralising antibody titre against SARS-CoV-2 (mechanistic substudy) and oral methotrexate biochemical adherence (mechanistic substudy). Analysis of B-cell memory and T-cell responses at baseline and weeks 4 and 12 will be investigated subject to obtaining additional funding. The principal analysis will be performed on the groups as randomised (ie, intention to treat). The difference between the study arms in anti-spike RBD antibody level will be estimated using mixed effects model, allowing for repeated measures clustered within participants. The models will be adjusted for randomisation factors and prior SARS-CoV-2 infection status. Ethics and dissemination: This study was approved by the Leeds West Research Ethics Committee and Health Research Authority (REC reference: 21/HRA/3483, IRAS 303827). Participants will be required to give written informed consent before taking part in the trial. Dissemination will be via peer review publications, newsletters and conferences. Results will be communicated to policymakers. Trial registration number: ISRCTN11442263. Funding: This publication was funded by the Efficacy and Mechanism Evaluation programme as a part of award number NIHR134607. This article reports on one component of the research award Vaccine Response On/Off Methotrexate (VROOM): does temporarily suspending methotrexate treatment for two weeks enhance COVID-19 vaccine response? A randomised controlled trial. For more information about this research please view the award page [https://fundingawards.nihr.ac.uk/award/NIHR134607] DOI: https://doi.org/10.1136/bmjopen-2022-062599